Key Highlights
- Moderna shares climbed more than 16% following the publication of Phase 3 trial data in the New England Journal of Medicine, demonstrating that its mRNA flu vaccine (mRNA-1010) surpassed a licensed standard-dose comparator in adults aged 50 and above.
- Following the company’s Q1 2026 earnings report, three Wall Street analysts increased their price targets: Evercore ISI moved to $50, Goldman Sachs raised to $49, and Piper Sandler began coverage with a Buy recommendation.
- Brief market attention was drawn to Moderna’s early-stage hantavirus research following outbreak reports on a cruise ship, though analysts emphasize no significant commercial potential exists.
- The company awaits an FDA decision on mRNA-1010 with a PDUFA target date of August 5, while similar regulatory reviews are ongoing in Europe, Canada, and Australia.
- Competitors Pfizer and BioNTech discontinued patient recruitment for a significant U.S. COVID vaccine study in the 50–64 age group due to insufficient enrollment.
Shares of Moderna were changing hands near $56 during Thursday’s session, reflecting a gain exceeding 16%, driven by compelling clinical trial outcomes, a series of bullish analyst revisions, and fleeting attention to hantavirus developments.
The primary catalyst was clear-cut: Phase 3 clinical trial findings for Moderna’s investigational mRNA-based influenza vaccine, designated mRNA-1010, appeared in the prestigious New England Journal of Medicine. The study demonstrated that the vaccine achieved its prespecified superiority endpoint when compared against an approved standard-dose seasonal influenza vaccine in individuals 50 years and older.
This represents a significant achievement. Demonstrating superiority over an already-approved vaccine in a peer-reviewed publication strengthens Moderna’s regulatory submission as it approaches a critical FDA milestone.
The regulatory agency has designated August 5 as the target action date under the PDUFA timeline for mRNA-1010. Additionally, the vaccine is undergoing regulatory assessment in European markets, Canada, and Australia, positioning the product for a potential international rollout upon approval.
Wall Street analysts contributed additional momentum to the rally. Evercore ISI increased its price objective from $35 to $50. Goldman Sachs elevated its target from $43 to $49. Piper Sandler launched coverage with a Buy recommendation. These revisions followed Moderna’s first-quarter 2026 financial results.
Hantavirus Outbreak Generated Brief Market Interest
A hantavirus cluster involving individuals aboard a Dutch-registered cruise vessel traveling from Argentina to Cabo Verde temporarily boosted Moderna shares during early market hours. Health authorities reported eight infections, including three fatalities, with five cases confirmed as the Andes virus strain — the sole hantavirus variant documented to enable limited person-to-person transmission.
World Health Organization officials characterized the public health threat as minimal. Dr. Maria Van Kerkhove stated unequivocally during Thursday’s media briefing: “This is not the start of a COVID pandemic.”
Evercore ISI identified a research partnership between Moderna and Korea University focused on hantavirus that began in 2023, but analysts were equally candid in their assessment. The firm stated it identifies “no meaningful revenue opportunity” stemming from the outbreak coverage and emphasized that Moderna’s hantavirus program “remains very early stage.” The company’s shares, analysts observed, “tends to trade on outbreak headlines well beyond the underlying commercial implications.”
Bottom line: while the hantavirus situation generated headlines, the influenza vaccine data and analyst upgrades provided the substantive drivers behind the stock’s advance.
Cruise Industry Stocks Declined on Health Concerns
Cruise operator equities experienced downward pressure following the hantavirus reports. Royal Caribbean shares declined approximately 2% during the session, while Carnival experienced a comparable decrease. Norwegian Cruise Line Holdings fell nearly 3%. Both Viking Holdings and Lindblad Expeditions recorded declines around 2.5%.
On the competitive landscape, Pfizer and BioNTech announced the termination of enrollment for a substantial U.S.-based COVID vaccine clinical trial involving adults between 50 and 64 years old, attributing the decision to inadequate participant recruitment. This development could potentially strengthen Moderna’s competitive position in the emerging vaccine market.
Broader equity markets provided a favorable backdrop, with the S&P 500 advancing 0.71%, the Dow Jones Industrial Average rising 0.21%, and the Nasdaq Composite gaining 1.16%.
Moderna’s stock concluded the previous trading session at $48.79. The upcoming August 5 FDA decision regarding mRNA-1010 now represents the next significant event on the company’s calendar.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
